Cardiovascular diseases still represent the major cause of death and invalidity in our Western society. Clinical and epidemiological studies have established that the prevalence and incidence of these diseases are associated with serum lipoprotein concentrations. In the last years there has been a growing interest for the protein moiety of the lipoproteins called the "apolipoproteins", the determination of which offers a more discriminative diagnosis for coronary heart disease.
The aim of the project is to assist in the standardization of apolipoprotein (Apo) assays. The project includes the preparation of purified Apo AI, Apo AII and possibly Apo B to be used as calibrators for the determination of these Apo's in serum. The next step will concern methodological development and might result in the certification of serum reference materials.
The purification of Apo AI and Apo AII is completed. The stability of the lyophilized preparations appears to be satisfactory. The certification analysis is performed by aminoacid analysis to assign a mass concentration to each of the purified Apo's. The Apo materials have been certified with the following mass concentrations :
for Apo AI, CRM 393 (1.06 +/- 0.05) g/l
for Apo AII, CRM 394 (0.321 +/- 0.019) g/l.
The results are presented in EUR report 13393 (1991).
Funding SchemeCSC - Cost-sharing contracts